Pharma Capital

ReNeuron CFO 'pleased' with reformulation of degenerative diseases treatment

Michael Hunt, chief financial officer for the stem cell specialist ReNeuron Group Plc (LON:RENE) updates Proactive on two of their clinical programmes.

Hunt says they're preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke.

He also mentions that a new formulation of their human retinal progenitor cell which is being trialled to treat degenerative diseases of the retina, represents a major step forward for them.

 

View full RENE profile

ReNeuron Group Plc Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.